Dicerna Pharmaceuticals
Dicerna Pharmaceuticals Inc (Form: 8-K, Received: 12/16/2015 16:04:38)

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): December 15, 2015

 

 

DICERNA PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-36281   20-5993609

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification Number)

87 Cambridgepark Drive

Cambridge, MA 02140

(Address of principal executive offices, including Zip Code)

Registrant’s telephone number, including area code: (617) 621-8097

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (See General Instruction A.2 below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4c))

 

 

 


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On December 15, 2015, Dicerna Pharmaceuticals, Inc. (the “Company”) announced that John “Jack” Green was appointed to serve as interim Chief Financial Officer of the Company on a part-time basis effective on January 1, 2016. Concurrently to serving as part-time, interim Chief Financial Officer of the Company, Mr. Green will continue in a part-time capacity as Chief Financial Officer of Verastem, Inc.

Mr. Green succeeds James Dentzer, the Company’s former Chief Financial Officer, who departed the Company on December 15, 2015. Mr. Dentzer’s departure was not due to any disagreement with the Company regarding its operations, financial reporting, policies or procedures.

Mr. Green has been the Chief Financial Officer of Verastem, Inc. since May 2013. Prior to joining Verastem, Inc., from March 2011 until December 2012, Mr. Green was Vice President, Finance and a key member of the senior management team for On-Q-ity Inc. and oversaw the financial activities, planning, budgeting and management of commercial and banking relationships. Prior to that, from May 2002 until June 2010, Mr. Green was the Senior Vice President and Chief Financial Officer of GTC Biotherapeutics (formerly Genzyme Transgenics Corporation). Mr. Green is a Certified Public Accountant. He holds a master’s degree in business administration from Boston University Graduate School of Management and a bachelor’s degree from College of the Holy Cross.

The Company hereby incorporates by reference the information relating to the appointment of Mr. Green and departure of Mr. Dentzer set forth in the press release issued on December 15, 2015, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

Item 9.01 Financial Statements and Exhibits.

(d) Exhibit

 

Exhibit
No.

  

Description

99.1    Press release titled “Dicerna Pharmaceuticals Appoints John ‘Jack’ Green Interim Chief Financial Officer” issued by Dicerna Pharmaceuticals, Inc. on December 15, 2015


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: December 16, 2015     DICERNA PHARMACEUTICALS, INC.
    By:  

/s/ Douglas M. Fambrough, III, Ph.D.

      Douglas M. Fambrough, III, Ph.D.
      Chief Executive Officer


EXHIBIT INDEX

 

Exhibit
No.

  

Description

99.1    Press release titled “Dicerna Pharmaceuticals Appoints John ‘Jack’ Green Interim Chief Financial Officer” issued by Dicerna Pharmaceuticals, Inc. on December 15, 2015

Exhibit 99.1

 

LOGO

Dicerna Pharmaceuticals Appoints John “Jack” Green Interim Chief Financial Officer

CAMBRIDGE, Mass. —(BUSINESS WIRE)— Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of RNA interference (RNAi) therapeutics, today announced the appointment of John “Jack” Green as interim chief financial officer (CFO), effective January 1, 2016. He replaces James Dentzer, whose departure is also announced today.

Mr. Green is a Certified Public Accountant with over 30 years of financial management experience, including more than 20 years within the biotechnology industry. Concurrently to serving as part-time, interim CFO at Dicerna, Mr. Green will continue in a part-time capacity as CFO of Verastem, Inc. (VSTM). Previously, he served for more than 15 years as CFO of GTC Biotherapeutics (formerly Genzyme Transgenics), a publicly traded biotech company spun out of Genzyme as a stand-alone company in 1993. Mr. Green received a Master’s degree in Business Administration from Boston University Graduate School of Management and a Bachelor of Arts degree from the College of the Holy Cross.

“We are pleased to welcome Jack Green as interim CFO, as his financial acumen will help guide us as we continue to advance our clinical development programs, while we seek to hire a permanent CFO,” said Douglas Fambrough, Ph.D., chief executive officer of Dicerna. “I would also like to thank Jim Dentzer for his years of service to Dicerna, and for being such a vital contributor to the company’s growth. We wish Jim well in his future endeavors.”

About Dicerna

Dicerna Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery and development of innovative treatments for rare, inherited diseases involving the liver and for cancers that are genetically defined. The company is using its proprietary RNA interference (RNAi) technology platform to build a broad pipeline in these therapeutic areas. In both rare diseases and oncology, Dicerna is pursuing targets that have been difficult to address using conventional approaches, but where connections between targets and diseases are well understood and documented. The company intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners.

Dicerna

Investor:

Westwicke Partners

Peter Vozzo, 443-213-0505

peter.vozzo@westwicke.com

or


Media:

SmithSolve

Alex Van Rees, 973-442-1555 ext. 111

alex.vanrees@smithsolve.com

Source: Dicerna Pharmaceuticals, Inc.